



Drug Discovery III



Conference Programme



Manchester Central, Manchester
7th & 8th September 2011



□ Welcome Words

Welcome to the fifth **Drug Discovery** meeting organized by **ELRIG** (European Laboratory Robotics Interest Group) and supported by the **SLAS** (Society for Laboratory Automation and Screening).

Since our first meeting in Nottingham in 2007 the Drug Discovery meeting has grown from strength to strength. The meeting has established itself as the major meeting place for scientists from pharma, biotech and academia interested in the challenges of pre-candidate drug discovery with over 1000 scientists attending the 2010 meeting in Coventry.

Our program in 2011 continues the themes established in previous years. Over the next two days a superb range of world-class Speakers will be presenting in eight sessions covering a wide range of topical issues for Drug Discovery from Enzymes and GPC targets to Robotics and Assay Development. Stem cells and their various applications are a common feature of many presentations: a reflection of the impact this exciting technology is having on our research. It is therefore with especial delight that we welcome Jamie Thomson, Wisconsin University as an additional Keynote speaker.

In addition, the meeting features an extensive array of posters, snapshot talks, training, several competitions and probably the best exhibition for Drug Discovery products and services in the UK which incorporates a thriving Innovation Zone for new companies promoting exciting technologies to the market. There are also a range of peripheral meetings and training courses.

The meeting will end with a debate on the relative merits and challenges of small molecules and biotherapeutics between Chris Lipinski, Melior Discovery, the creator of the "Rule of Five", and Kevin Johnson, Index Ventures and formerly the Chief Technology Officer at Cambridge Antibody Technology.

As in past years registration and attendance at the show is FREE – we can only do this because of the support of our sponsors and exhibitors.

In developing the program for this meeting ELRIG is placed at the centre of our community with the objective of bringing together scientists from across the field, whether they are based in academia, the pharmaceutical or biotech industries, in order to establish relationships to advance the science of drug discovery in the UK and Europe.

We will be back at the same venue on 5th & 6th September next year so please make a date in your diary!

With best regards,

Adrian Kinkaid and Stephen Rees
Program Chairs Drug Discovery 2011



CONFERENCE OVERVIEW

The provision of Stem Cells and their derived progeny is one of the most promising high impact developments in modern medical science. In pharmaceutical research they have been harnessed to provide a plethora of highly characterised cells for a wide range of applications. More direct applications of stem cells are also enabling the development of a whole new field of therapy, Regenerative Medicine, focusing on the underlying causes of diseases by effectively replacing or regenerating the damaged cells themselves. This conference will highlight state of the art research and technology enabling the provision of stem cells, their differentiation into desired cell types as well as applications as potential therapeutic agents.

Confirmed Speakers

Malcolm Alison, QMUL
Stephen Minger, GE
Marc Peschanski, I-STEM

Julie Daniels, UCL
David Williams, Loughborough University
Christian van den Bos, R & D, Lonza
Sebastian Greenhough, Edinburgh University

For more information contact Jackie Howard
Telephone: 07879 050 555 or Email: Jackie.howard@elrig.org

About ELRIG □

ELRIG is a **Not For Profit** special interest group focused on the use of automation, robotics and instrumentation in the laboratory and also on the wider applications of laboratory automation.

Our membership consists of scientists, researchers, engineers, developers and business-people who are interested in robotics, automation and associated technological developments in this field.

Our primary objective is to provide an open communication forum for users and vendors, within which members can be educated, share information and experience and network with other members.

Our primary means of achieving this is to **organise Meetings and Conferences** in which our members' experiences of automation are presented and at which relevant vendors exhibit their latest technology. Our aim is to provide world-class meetings and conferences which are accessible to all.

In order to meet our open-access aims, we operate a business model in which delegate access to our meetings is **Free of Charge**. We aim to cover the cost of staging our events from the contributions of the exhibitors and sponsors.

About SLAS □

The Society for Laboratory Automation and Screening (SLAS) is an international community of more than 10,000 individual scientists, engineers, researchers, technologists and others from academic, government and commercial laboratories. SLAS provides forums for education and information exchange to encourage the study of and advance laboratory science and technology for the drug discovery, agrochemical, biotechnology, chemical, clinical diagnostic, consumer product, energy, food, forensic, pharmaceutical, security and other industries.

SLAS works hard to deliver tangible educational programs and services to its members. Professionals at all levels who actively invest their time and energy in their SLAS memberships often experience immeasurable returns on their investments. Those who contribute as volunteers and committee members enjoy even greater advantages.

Scientific education, practical information, professional career-building, and valuable networking opportunities can open many doors to personal and professional success. Acknowledge your role in the unique field of laboratory science and technology. Join the only international, non-profit society devoted exclusively to your best interests. **Join SLAS today at SLAS.org.**

About BPS □

The BPS is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry and the health services and many are medically qualified. The Society covers the whole spectrum of pharmacology, including the laboratory, clinical and toxicological aspects.

The BPS exists to promote and advance pharmacology (including without limit, clinical pharmacology) and to be the leading Society for the presentation, promotion and discussion of all matters relating to both pharmacology, clinical pharmacology and therapeutics (CPT). Specifically, the Society is concerned with the discovery, mechanism of action, use and safety of drugs in humans and animals, in order to contribute to education and the understanding and relief of suffering.

The Society is a registered Charity. The Society's governing document is its Memorandum, Articles of Association and Rules. In 1994, the Society became a Company Limited by Guarantee.

Jamie Thomson



Dr. Jamie Thomson graduated with a B.S. in biophysics from the University of Illinois in 1981.

He entered the Veterinary Medical Scientist Training Program at the University of Pennsylvania, receiving

his doctorate in veterinary medicine in 1985, and his doctorate in molecular biology in 1988. He derived the first human embryonic stem (ES) cell line in 1998 and derived human induced pluripotent stem (iPS) cells in 2007. He serves as Director of Regenerative Biology at the Morgridge Institute for Research in Madison, Wisconsin, is a professor in the Department of Cell and Regenerative Biology at the University of Wisconsin's School of Medicine and Public Health and a professor in the Molecular, Cellular, and Developmental Biology Department at the University of California, Santa Barbara.

He is also a founder and Chief Scientific Officer for Cellular Dynamics International, a Madison-based company producing derivatives of human induced pluripotent stem cells for drug discovery and toxicity testing.

Christopher Lipinski



Dr. Christopher Lipinski achieved the highest scientific position at Pfizer after a 32 year career in early drug discovery research.

He is a Scientific Advisor to Melior Discovery a drug repurposing startup. An American Chemical Society, American Association of Pharmaceutical Sciences and Society for Laboratory Automation Screening member he is the author of the "rule of five" the most highly cited publication in Medicinal Chemistry. He is a member of the ACS "Medicinal Chemistry Hall of Fame" and the winner of the ACS' E. B. Hershberg award in Medicinal Chemistry and the Society of Biomolecular Sciences Achievement award.

He has an honorary doctor of laws degree from the University of Dundee and is an adjunct professor in Biochemistry at the University of Massachusetts Amherst and has over 250 publications and invited presentations and 18 issued US patents.

Kevin Johnson



Kevin Johnson is a Partner at Index Ventures working out of the London office.

Prior to that he was CEO of PanGenetics, an antibody development company based in the Netherlands, and one of the Index Ventures portfolio. Kevin was one of the team at Cambridge Antibody Technology (CAT), heading up research from 1994 onwards. In 1997 he was appointed to the Board, where he held the posts of Research Director and Chief Technology Officer. Kevin led both the development of CAT's platform technologies, and also their application to the discovery of a number of human antibodies currently in clinical development. Two of these are now marketed, Humira (Abbott Pharmaceutical) and Benlysta (HGS, GSK). He was also part of the management team that floated CAT on the London Stock Exchange (main market).

Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.



ELRIG Presents The SLAS Young Scientist Award



Students, graduates and post-docs are welcome to compete for the SLAS Young Scientist Award at the ELRIG Drug Discovery 2011 Annual Conference and Exhibition, September 7-8, at Manchester Central, United Kingdom.

The winner will be invited to present and participate in the Student Poster Competition at the 1st Annual SLAS Conference and Exhibition, February 4-8, 2012, at the San Diego Convention Center, San Diego, CA, USA.

SLAS Young Scientist Award winners receive a \$500 cash prize, roundtrip coach airfare, shared hotel accommodations and conference registration for SLAS2012.



□ Lonza lunchtime tutorials

Venue: Manchester Central, Manchester - Room Central 8

Lonza

Wednesday September 7

- 12.35 – 13.25 Pathway Selectivity Profiling Using NodeSensor™ PCA technology
- Anthony Pitt
- 13.25 – 14.15 Strategies for Primary and Stem Cell Supply in Discovery
- Alex Batchelor

Thursday September 8

- 12.25 – 13.15 Measuring Calcium and cAMP Signalling from Endogenous Targets in Primary Cells
- Anthony Pitt

Registration:

At ELRIG registration desk, Lonza stand A3, or at www.lonza.com/elrig-dd2011

Places are FREE – but are limited.

□ Career Zone

Jobs Postings - Advisors - One-to-One advice sessions:

George James Ltd

George James Ltd are again pleased to be able to support the Careers Zone at the ELRIG DD show. Half hour sessions are available to delegates and exhibitors who wish to discuss any matters relating to:

How best to recruit in today's market, how to maximise the effectiveness of a job search, advice on CV writing, how to prepare for and manage an interview, as well as tips on effective career development. In addition to the half hour discussion, additional resources will be available to provide further information on the topic of interest. To book a session please contact Neil Burns on neil.burns@georgejamesltd.co.uk or call him at the show on 07977 988000 to arrange a time to meet.

Langton Howarth

Langton Howarth is a specialist recruitment consultancy working within the Life Science, Diagnostic, Healthcare and Consumer Health and Beauty industries. We offer an unparalleled quality of service and a consistent commitment towards our clients and candidate, and aim for nothing short of excellence. Visit us at the Careers Zone for unbiased advice about your future career move or current recruiting needs.

**If you are looking for a job, or looking for people,
where better than ELRIG to network?**



Drug Discovery Product of the Year Announcement

Wednesday at 5.00pm, Exhibit Hall

Join us during the drinks reception for the 4th Annual Scientists' Choice Awards at the ELRIG Meeting. Learn which product has won the celebrated 'Product of the Year Award', recognising technologies making a difference in Drug Discovery labs each year. The Scientists' Choice Awards are hosted by SelectScience.

Last year's winner, selected by SelectScience.net members worldwide, was the FLUOstar Omega Multidetection Microplate Reader by BMG LABTECH. If you miss the presentation, visit www.scientistschoiceawards.com for more information.



(Picture: Michael Fejt, BMG LABTECH, accepting the award from Arif Butt, Publisher of SelectScience at ELRIG Drug Discovery 2010, Coventry)

Unwind with us
at our

DRINKS RECEPTION

Wednesday 7th September 2011
at 5.00 – 7.00 pm

Join us in the Exhibition Hall

Bring your Drinks Tickets and see them magically
turn into Wine, Beer or soft drinks

Be entertained and amazed by our 'Close Up Magician'
– Alistair, the very best in Close Up Magic



slas
2012

1st annual
CONFERENCE & EXHIBITION

San Diego Convention Center
San Diego, CA, USA | February 4–8, 2012

Short Courses: February 4–5
Conference: February 6–8
Exhibition: February 6–7

Collaborate • Innovate • Dominate

Collaborate with 5,000+ innovative scientists, engineers, researchers and technologists from academic, government and commercial laboratories around the globe to **inaugurate** the First Annual SLAS Conference and Exhibition (SLAS2012) in San Diego, CA, USA, February 4–8, 2012.

Stimulate your scientific creativity through 100+ outstanding educational sessions. **Investigate** new and emerging technologies from 250+ exhibitors. **Calibrate** your personal goals, **accelerate** your professional success and **dominate** the field of laboratory science and technology.

Validate your potential. Register now at SLAS2012.org!

 **slas** | SOCIETY FOR
LABORATORY AUTOMATION
AND SCREENING
An International Community Advancing Scientific
Research and Discovery Through Laboratory Technology

 **SBS** | SOCIETY OF
BIOMEDICAL SCIENTISTS

 **ALA** | ASSOCIATION
OF LABORATORY AUTOMATION



Session 1 Day 1 – 7th September

GPCR Drug Discovery



9.00 – 9.05 9.00 – 9.15	Introductions and Welcome	Graeme Milligan, Glasgow University Steve Garland
9.15 – 10.00	Session Keynote Stephen Liggett, Maryland University	Bitter Taste Receptors on Airway Smooth Muscle Couple to a Restricted Ca ²⁺ Pool and their Agonists are Highly Efficacious Bronchodilators
10.00 – 10.30	Paola Casarosa, Boehringer-Ingelheim	Olodaterol: a novel B2 agonist with once daily potential. Possible rationales for long duration of action
10.30 – 11.00	COFFEE BREAK	
11.00 – 11.30	Patricia Rene, Montreal University	Pharmacological Chaperones: Potential Therapeutic approach to treat MC4R-Linked early onset obesity?
11.30 - 12.00	Stephen Hunt, Anchor Therapeutics	Development of Pepducin Therapeutics: Allosteric Peptide Modulators of G Protein-Coupled Receptors
12.00 – 12.30	SNAPSHOTS	<i>Cellectis, CellAura, Vectalys</i>
12.30 – 2.30	LUNCH/EXHIBITION	POSTER VIEWING
2.30 – 3.00	Andrew Tobin, Leicester University	Can the phosphorylation profile of GPCRs drive functionality?
3.00 – 3.30	Conrad Cowan, Trevana	GPCR biased ligands; from theory to practice
3.30 – 4.00	James Bailey, GSK	Discovery of selective S1P1 agonists efficacious at low oral dose and devoid of adverse cardiovascular signal
4.00 – 5.00	POSTER PRESENTATIONS	EXHIBITION HALL
5.00 – 7.00	DRINKS RECEPTION	EXHIBITION HALL



Session 2 Day 1 – 7th September

Assay Development and Screening



9.00 – 9.05 9.00 – 9.15	Introductions and Welcome	Richard Eglen, Corning Jeff Paslay
9.15 – 10.00	Session Keynote Richard Eglen, Corning	High Throughput Screening and Assay Development – Fit For Purpose?
10.00 – 10.30	Steve Rees, AstraZeneca	High Throughput Screening: Historical Success and Future Perspectives
10.30 – 11.00	COFFEE BREAK	
11.00 – 11.30	Paul van Midwoud, Groningen University	Microfluidics Enables Small-Scale Tissue-Based Metabolism Studies using Human and Rat Precision-Cut Tissue Slices
11.30 - 12.00	Gary Clark, BioFocus	Early experiences with the Dynaflo HT, a microfluidics-based multichannel automated electrophysiology platform
12.00 – 12.30	SNAPSHOTS	<i>Ziath, Nanion, TTP, The Research Network</i>
12.30 – 2.30	LUNCH/EXHIBITION	POSTER VIEWING
2.30 – 3.00	Stuart Baddeley, GSK	Enabling Lead Discovery at Epigenetics Targets with RapidFire™ Mass Spectrometry
3.00 – 3.30	Frank Stuhmeier, Pfizer	Label free primary screening of 7TMRs – a superior approach to identify agonists and PAMs?
3.30 – 4.00	Helen Boyd, Pfizer	HTS Approaches To Epigenetics
4.00 – 5.00	POSTER PRESENTATIONS	EXHIBITION HALL
5.00 – 7.00	DRINKS RECEPTION	EXHIBITION HALL



Session 3 Day 1 – 7th September

Biological Sample Management

9.00 – 9.05	Introductions and Welcome	Glyn Stacey, UN Stem Cell Jonathan Wingfield, AstraZeneca
9.00 – 9.15		
9.15 – 10.00	Session Keynote Pasquale de Blasio, ESBB BioRep	Management of Stem Cells within the Biobanking Industry
10.00 – 10.30	Paul Downey, UK BioBank	Considerations in the Management of the finite UK Biobank sample resource to maximise its scientific research utility
10.30 – 11.00	COFFEE BREAK	
11.00 – 11.30	Chris Womack, AstraZeneca	Human sample biorepositories and infrastructure to enable drug discovery at AstraZeneca
11.30 - 12.00	Jane Rogan, MCRC BioBank	Establishing a regional multi-centre Cancer BioBank
12.00 - 12.30	Matt Sims, MRC Cambridge	From Biological Sample to Genetic Loci: Automating Large-Scale Epidemiological Research
12.30 – 2.30	LUNCH/EXHIBITION	POSTER VIEWING
2.30 – 3.00	Christer Ericsson, Karolinska Institute	Circulating Tumor Cells the Grand Challenge... and a tentative solution
3.00 – 3.30	Daniel Brison, NW Embryonic SCC	Biobanking of gametes, embryos and reproductive tissues: preserving and extending fertility
3.30 – 4.00	Mike Byrom, BioEden	Bio-Banking of Adult Stem Cells
4.00 - 4.15	SNAPSHOTS	<i>CryoGaTT, Automation Trainer</i>
4.15 – 5.00	POSTER PRESENTATIONS	EXHIBITION HALL
5.00 – 7.00	DRINKS RECEPTION	EXHIBITION HALL



Session 4 Day 1 – 7th September

Safety Profiling in Early Discovery

9.00 – 9.05 9.00 – 9.15	Introductions and Welcome	Julie Holder, GSK Laszlo Urban, Novartis
9.15 – 10.00	Session Keynote Peter O'Brien, UCD	High Content Analysis of Cytotoxicity for Prediction, Mechanistic Elucidation and Blood Biomarkers of Human Toxicity
10.00 – 10.30	Chris Denning, Nottingham University	Progress and challenges of automating culture of human pluripotent stem cells
10.30 – 11.00	COFFEE BREAK	
11.00 – 11.30	Steve Beasley, Gentronix	Moving attrition. Easier said than done? The case for early genetic toxicology prediction
11.30 - 12.00	Kristina Tressat, Axiogenesis	Mouse Embryonic Stem Cell Derived Cardiomyocytes and the RTCA Cardio Instrument – The Perfect Match for Screening Cardiac Effects
12.00 – 12.30	SNAPSHOTS	<i>Roche, Zyoxel</i>
12.30 – 2.30	LUNCH/EXHIBITION	POSTER VIEWING
2.30 – 3.00	Laszlo Urban, Novartis	Early safety assessment of drug candidates: Utility of in vitro pharmacological profiling
3.00 – 3.30	Murray Brown, GSK	In Vitro Safety Profiling During Lead Optimisation
3.30 – 4.00	Matt Segall, Optibrium	Multi-parameter Optimisation in Drug Discovery: Quickly targeting compounds with a good balance of properties
4.00 – 5.00	POSTER PRESENTATIONS	EXHIBITION HALL
5.00 – 7.00	DRINKS RECEPTION	EXHIBITION HALL



Session 1 Day 2 – 8th September

Enzyme Drug Discovery

8.30 – 8.35	Introductions and	David Gray, Dundee University
8.30 – 8.45	Welcome	Catherine Kettleborough, MRC Technologies
8.45 – 9.30	Session Keynote Richard Bickerton, Dundee University	Chemistry driven target selection
9.30 – 10.00	Matthew Freeman, MRC	Identifying the first inhibitors of rhomboid intramembrane proteases
10.00 – 10.30	Alan Lau, AstraZeneca	DNA damage response (DDR) enzymes as therapeutic targets in oncology
10.30 – 11.00	SNAPSHOTS	
11.00 – 11.30	COFFEE BREAK	
11.30 – 12.20	KEYNOTE Jamie Thomson, Wisconsin University	Current State of Induced Pluripotent Stem cells as compared to Embryonic Stem cells and their role in creating terminal tissue models
12.20 – 1.45	LUNCH/EXHIBITION	POSTER VIEWING
1.45 – 2.15	Tom Heightman, Astex Therapeutics	Fragment Based Drug Discovery in Academia and Biotech
2.15 – 2.45	James Leiper, Imperial College	The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis
2.45 – 3.15	Benjamin Bax, GSK	Structure-based studies on the inhibition of a DNA supercoiling machine
3.15 – 3.45	COFFEE BREAK	
3.45 – 5.00	KEYNOTE DEBATE Chris Lipinski, Melior Discovery Kevin Johnson, Index Ventures	'The Future of Drug Discovery – Small Molecules & Biopharmaceuticals'
5.00 – 5.15	CLOSE OF CONFERENCE FEEDBACK FORM PRIZE DRAW	Steve Rees, SLAS and Adrian Kinkaid, ELRIG



Session 2 Day 2 – 8th September

Robotics and Automation



8.25 – 8.30	Introductions and Welcome	Andy Zaayenga, High Res Colin Bath, AstraZeneca
8.30 – 9.00	Dale Larson, CryoXtract Instruments	Development of an Automated Frozen Sample Aliquotter
9.00 – 9.30	Alberto Bresciani, IRBM	The Italian Chemical Collection and Screening Initiative: setting up strategies and automation
9.30 – 10.00	Tara Dalton, Life Technologies	High Throughput qPCR Gene Expression Screening Enabled by Nanofluidic Droplets
10.00 – 10.30	Annes Lambert, Manchester University	Implementation of Automated Cell Culture and Cell Assay Platforms within the University of Manchester Centre of Excellence in Biopharmaceuticals
10.30 – 11.00	SNAPSHOTS	<i>Hamilton, Labcyte, Cybio, Aglient, Caliper, Photophysics</i>
11.00 – 11.30	COFFEE BREAK	
11.30 – 12.20	KEYNOTE Jamie Thomson, Wisconsin University	Current State of Induced Pluripotent Stem cells as compared to Embryonic Stem cells and their role in creating terminal tissue models
12.20 – 1.45	LUNCH/EXHIBITION	POSTER VIEWING
1.45 – 2.15	Namyong Kim, Curiox Biosystems	Introducing DropArray™ Technology for ELISA and Cell Assays
2.15 – 2.45	Eric Tang, AstraZeneca	Automation of High Throughput Imaging Cell-based Assay workflow and impact of SHE compliance – meet the challenges or a step too far?
2.45 – 3.15	Dave Parry, Cyclofluidic	An automated integrated approach for SAR generation
3.15 – 3.45	COFFEE BREAK	
3.45 – 5.00	KEYNOTE DEBATE Chris Lipinski, Melior Discovery Kevin Johnson, Index Ventures	'The Future of Drug Discovery – Small Molecules & Biopharmaceuticals'
5.00 – 5.15	CLOSE OF CONFERENCE FEEDBACK FORM PRIZE DRAW	Steve Rees, SLAS and Adrian Kinkaid, ELRIG



Session 3 Day 2 – 8th September

Cellular Imaging Technologies



8.30 – 8.35	Introductions and	Stephen Hill, Nottingham University
8.30 – 8.45	Welcome	Rod Benson, Imagen Biotech
8.45 – 9.30	Session Keynote Mike White, Manchester University	Application of systems biology approaches to study cell signalling and transcription
9.30 – 10.00	Roy Katso, GSK	Configuration of mechanistic high content imaging assays for histone demethylases
10.00 – 10.30	Anthony Pitt, Lonza	High-content analysis of signalling networks using protein fragment complementation assays (PCA)
10.30 – 11.00	SNAPSHOTS	<i>Beckman Coulter, PerkinElmer, Imagen Biotech</i>
11.00 – 11.30	COFFEE BREAK	
11.30 – 12.20	KEYNOTE Jamie Thomson, Wisconsin University	Current State of Induced Pluripotent Stem cells as compared to Embryonic Stem cells and their role in creating terminal tissue models
12.20 – 1.45	LUNCH/EXHIBITION	POSTER VIEWING
1.45 – 2.15	Darren Cawkill, Pfizer	A Quantitative Plate-Based Assay to Screen for Changes in Gene Expression within Pain Pathways of Primary Rat Sensory Neurons
2.15 – 2.45	Kevin Pflieger, Dimerix Bioscience	G-Protein Coupled Receptor Heteromers and Drug Discovery
2.45 – 3.15	Leigh Stoddart, Nottingham University	Fluorescence based live cell binding assays for GPCRs
3.15 – 3.45	COFFEE BREAK	
3.45 – 5.00	KEYNOTE DEBATE Chris Lipinski, Melior Discovery Kevin Johnson, Index Ventures	'The Future of Drug Discovery – Small Molecules & Biopharmaceuticals'
5.00 – 5.15	CLOSE OF CONFERENCE FEEDBACK FORM PRIZE DRAW	Steve Rees, SLAS and Adrian Kinkaid, ELRIG







































































Session 4 Day 2 – 8th September

Cell Systems for Drug Discovery

CORNING

8.30 – 8.35	Introductions and	Katy Gearing, GSK
8.30 – 8.45	Welcome	Mike Jowett
8.45 – 9.30	Session Keynote Chris Kendrick-Parker, Cellular Dynamics	Induces Pluripotent derived terminal tissues for drug discovery and development: An industrialized approach
9.30 – 10.00	Chris Torrance, Horizon Discovery	Patient-relevant disease models for targeted drug discovery and cell-based screening applications
10.00 – 10.30	Robert Brown, UCL	Rapid, Multi-Well Fabrication of Living 3D-Tissue Models for Testing & Controlled Release
10.30 – 11.00	SNAPSHOTS	<i>Corning, Stem Cell Technology, Maxcyte, InSphero</i>
11.00 – 11.30	COFFEE BREAK	
11.30 – 12.20	KEYNOTE Jamie Thomson, Wisconsin University	Current State of Induced Pluripotent Stem cells as compared to Embryonic Stem cells and their role in creating terminal tissue models
12.20 – 1.45	LUNCH/EXHIBITION	POSTER VIEWING
1.45 – 2.15	Andrew Griffiths, Strazborg University	Miniaturising the Laboratory in Droplets
2.15 – 2.45	Caroline Freathy, Asterand	Human primary cell based assays – a challenge but worth it in the end!
2.45 – 3.15	James Root, Pfizer	Use of fresh human tissue in pharmaceutical research
3.15 – 3.45	COFFEE BREAK	
3.45 – 5.00	KEYNOTE DEBATE Chris Lipinski, Melior Discovery Kevin Johnson, Index Ventures	'The Future of Drug Discovery – Small Molecules & Biopharmaceuticals'
5.00 – 5.15	CLOSE OF CONFERENCE FEEDBACK FORM PRIZE DRAW	Steve Rees, SLAS and Adrian Kinkaid, ELRIG

Exhibitors List

4titude Ltd		Essen BioScience Ltd		ReTiSoft, Inc	
Affymetrix		FluidX		Roche Diagnostics Limited	
Agilent Technologies		Genetix Ltd		RTS Life Sciences	
Almac Group Ltd		Genevac		Scottish Biomedical	
AlphaBiotec Ltd		Gentronix Limited		Sigma-Aldrich	
Applied Photophysics Ltd		Greiner Bio-One		Sirius Analytical	
Assaymetrics Limited		Hamamatsu Photonics UK Ltd		Stemcell Technologies	
Astech Projects		Hamilton Robotics Ltd		TAP Biosystems	
Aurelia Bioscience		Highres Biosolutions		Tecan UK Ltd	
Beckman Coulter		HPA Culture Collections		Thermo Fisher Scientific	
Bigneat Containment Technology		Innoprot		Titian Software Ltd	
Biocair		InSphero AG		TTP Labtech	
BioFocus		Integrated DNA Technologies		Vectalys	
BioTek Instruments Limited		IntelliCyt Corporation		Ziath Ltd	
BMG Labtech		Kbiosystems/ Wildcat Laboratory Solutions		Zinsser Analytic UK Ltd	
Caliper Life Sciences Ltd		Labcyte Inc.		<div style="border: 1px solid black; padding: 5px;"> <p>INNOVATION ZONE:</p> <p>Amebis</p> <p>CryoGaTT</p> <p>Flexible Lab Solutions</p> <p>Imagen Biotech</p> <p>InSCREENeX GmbH</p> <p>INTAVIS Bioanalytical Instruments</p> <p>Semba Biosciences</p> <p>The Research Network</p> <p>Ubiquigent</p> <p>Venomtech Ltd</p> <p>Zyoxel Ltd</p> </div>	
Caltag Medsystems Ltd		Laboratory Consumable Supplies Limited (LCS)			
Cambridge Bioscience		Liconic UK Ltd			
CCS Cell Culture Service		Life Technologies			
CellAura Technologies Ltd		Lonza			
Collectis Bioresearch		MaxCyte			
Cisbio Bioassays		Merck Millipore			
Computype		Molecular Devices			
Contained Air Solutions Limited		MRC Technology			
Corning Life Sciences		Nanon Technologies GmbH			
CyBio Northern Europe Ltd		NEXUS Biosystems AG			
Dotmatics		PerkinElmer			
Enzo Life Sciences (UK) Ltd		PharmaDiagnostics			
Eppendorf UK		Promega UK Ltd			



ELRIG 2012 Meetings



13TH MARCH 2012

Diagnostics

The Belfry, Oxford



26TH JUNE 2012

Next Generation Sequencing

Hinxton Hall, Cambridge



5TH AND 6TH SEPTEMBER 2012

DD:2012

Sessions

1. Lead Identification for Epigenetic Enzymes
2. Fragment Discovery for Enzyme & Membrane Targets
3. Nano-Technologies: Beyond the Microtitre Plate
4. Primary & Stem Cells: Tissue Generation
5. Ubiquitin Drug Discovery
6. Informatics: Making Knowledge from Lab Data
7. Biophysics & Label Free Technologies
8. Compound Collection Enhancement & Management

Manchester Central



10TH AND 11TH OCTOBER 2012

Flow Cytometry and Imaging

AZ, Alderley Park



For more information please contact: Jackie Howard, Conference Organiser
Email: jackie.howard@elrig.org Mobile: +44(0)7879 050 555

□ Founding Sponsors

